Skip to main navigation
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Tablet
    • MVT-602
  • OUR MEDICINES
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
      • Press Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Board of Directors
      • Documents & Charters
      • Committee Composition
      • Expanded Access
    • Email Alerts
  • Contact Us
  • Twitter
  • LinkedIn

Press Releases

Press Releases

January 26, 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Toolkit

Print Page
RSS Feeds
Email Alerts
Contact
Search
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Tablet
    • MVT-602
  • OUR MEDICINES
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
    • Stock Information
    • Financials & Filings
    • Corporate Governance
    • Email Alerts
  • Contact Us
© 2023 Myovant Sciences GmbH. All rights reserved.
Terms of Use Privacy Policy Cookie Policy Compliance & Prescriber Information